Hematopoietic Stem Cell Transplantation (HSCT) Market Upcoming Trends, Demand and Analysis Till 2026

Hematopoietic Stem Cell Transplantation (HSCT)
Market Usage, Dosage And Side Effects Analysis
2018 to 2026
Hematopoietic Stem Cell Transplantation (HSCT) Market, by Indication
(Leukemia, Lymphatic Disorder, Myeloma, Other Non-malignant Disorders), by
Application (Peripheral Blood Cells, Bone Marrow, Umbilical Cord Blood), and by
Geography - Global Industry Insights, Trends, Outlook, and Opportunity
Analysis, 2018-2026
Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells
sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a
patient. Hematopoietic stem cell transplantation is commonly used in the treatment of lymphoma
(Hodgkin, Non-Hodgkin), leukemia, multiple myeloma, thalassemia, sickle cell anemia, and
osteoporosis. It includes two transplantation sources namely, autologous that uses stem cells from the
patient’s own body and allogeneic that sources stem cells from a donor’s body. Click To Read More on
Hematopoietic Stem Cell Transplantation (HSCT) Market.
Rising incidence of leukemia and lymphoma and continuous research on hematopoietic stem cells
are expected to drive market growth
As per 2017 report by Leukemia and Lymphoma Society, the U.S. alone is expected to account for a
prevalence of 8,16,834 and incidence of 80,500 for lymphoma. Increasing rate of incidence is in turn,
expected to increase the demand for hematopoietic stem cell transplantation thus, propelling growth of
the hematopoietic stem cell transplantation (HSCT) market. Increasing awareness about stem cell
therapies among the population is also expected to propel growth of the hematopoietic stem cell
transplantation market. As per survey by World Network for Blood and Marrow Transplantation
(WBMN), around one million hematopoietic stem cell transplantation procedures were performed
during 2006 to 2014, which indicates potential opportunities for market players.
However, high costs associated with hematopoietic stem cell transplantation procedures are expected to
hinder growth of the market. Other factors such as difficulty in finding a donor for allogeneic
transplantation, technological barriers (currently used culture technologies, point of care delivery, and
lack of analytical assay), and side effects such as graft vs. host disease, are also expected to slow down
growth of the hematopoietic stem cell transplantation market.
Global Hematopoietic Stem Cell Transplantation Market Taxonomy
On the basis of indication:
•Leukemia
•Lymphatic disorder
•Myeloma
•Other non-malignant disorders
Immunodeficiency syndrome)
On the basis of application:
•Peripheral blood cells
•Bone marrow
•Umbilical cord blood
(thalassemia,
sickle
cell
anemia,
Osteoporosis,
Important players present in the hematopoietic stem cell transplantation market
Major players operating in the hematopoietic stem cell transplantation market include Pluristem
Therapeutics Inc., CellGenix Technologie Transfer GmbH, Kite Pharma Inc., Regen Biopharma Inc.,
BiolineRx, Cynata Therapeutics, Lonza Group Ltd, Cesca Therapeutics Inc, TiGenix N.V., Escape
Therapeutics Inc., Bluebird Bio, and Cellular Dynamics International.
Increasing adoption of the growing trend of personalized medicine is expected to drive growth of the
hematopoietic stem cells transplantation market. A collaborative research study on hematopoietic stem
cell transplantation initiated by World Network for Blood and Marrow Transplantation (WBMN) in
2013 in the domain of promotion of access to hematopoietic stem cell transplantation, developed a
donation guidance document, technical and scientific input on safety, and quality of HSCT as
mentioned in annual report of the WBMN.
Ask For Sample Copy Of This Business Research Report :
https://www.coherentmarketinsights.com/insight/request-sample/1250
In March 2017, Gilead Sciences announced the acquisition of Kite Pharma, which produces products
such as Axi-cel to treat non-Hodgkin lymphoma. Plasticell, which specializes in the development of
stem cell technologies and cell-based therapies, announced entering into an agreement with Nan yang
Technological University (NTU) in Singapore on March 2017, to advance its therapeutic stem cell
pipeline. Plasticell also announced collaboration with Anthony Nolan, a research organization in blood
cancer, to progress clinical development of Plasticell’s ex vivo expanded cord blood-derived
hematopoietic stem cell product in December 2017.
Also, Coherent Market Insights has a proprietary database of pipeline biologics and biosimilars, called
PHASE-XS. This database provides analytical data in addition to the clinical information of ongoing
trials for biologics and biosimilars. An amalgamation of more than 30 parameters, PHASE-XS helps
biotechnology and pharmaceutical companies to analyze the market trend, competition, and market
potential. For more information or to access this database, kindly click on the below link or contact at
[email protected]
https://www.coherentmarketinsights.com/phase-xs/
About Coherent Market Insights:
Coherent Market Insights is a prominent market research and consulting firm offering action-ready
syndicated research reports, custom market analysis, consulting services, and competitive analysis
through various recommendations related to emerging market trends, technologies, and potential
absolute dollar opportunity.
Contact Us:
Mr. Shah
Coherent Market Insights
1001 4th Ave, #3200
Seattle, WA 98154
Tel: +1–206–701–6702
Email: [email protected]

Hematopoietic stem cell transplantation is a procedure in which multipotent hematopoietic stem cells sourced from peripheral blood cells, bone marrow or umbilical cord blood are transplanted into a patient.